Publications by authors named "Grant L Steele"
Background: Despite mandated insurance coverage since 2006 and robust health infrastructure in urban settings with high concentrations of minority patients, race-based disparities in prostate cancer (PCa) treatment persist in Massachusetts. In this qualitative study, the authors sought to identify factors driving inequities in PCa treatment in Massachusetts.
Methods: Four hospitals offering PCa treatment in Massachusetts were selected using a case-mix approach.
Article Synopsis
- The purpose of the systematic review was to investigate racial and ethnic disparities in access to germline genetic testing (GGT) for prostate cancer among Black men and other marginalized groups, as this testing is important for cancer risk assessment and treatment.
- The review analyzed studies published between 1996 and 2021, finding that of 91 studies, only a small number (4) reflected GGT rates in routine clinical care, showing a significant underrepresentation of Black men compared to White men.
- The conclusion highlights that most GGT data comes from research settings rather than clinical practice and that there's a lack of representation for other marginalized populations, indicating a significant gap in understanding racial disparities in GGT usage.
Objectives: Pancreatic adenocarcinoma is frequently associated with pain requiring opioid therapy. Opioids, however, have been implicated in causing tumor progression, ultimately shortening survival. We examined the impact of pain, opioid use, and the mu-opioid receptor (MOP-R) expression in tumor tissue on progression-free survival and overall survival of patients with metastatic pancreatic cancer.
View Article and Find Full Text PDFBackground: Use of electronic patient-reported outcomes (ePROs) in routine cancer care can help identify troublesome symptoms and facilitate discussions between patients and clinicians and has been shown to improve patient satisfaction, quality of life, and survival.
Methods: Eighty patients with stage IV non-hematologic malignancies on chemotherapy participated. Patient-Reported Symptom Monitoring (PRSM) surveys were sent every 14 days via the Epic MyChart system over a 12-week period.